Skip to Content

Join the 'Mantle Cell Lymphoma' group to help and get support from people like you.

Mantle Cell Lymphoma News

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated. "Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology. ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Hodgkin's Lymphoma, Burkitt Lymphoma, Diagnosis and Investigation, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white blood cell in which most types of non-Hodgkin lymphoma occur. One-third of 32 patients treated with the modified T-cells experienced a complete remission of their non-Hodgkin lymphoma. And those pretreated with more aggressive chemotherapy did even better, researchers report. "It's a fantastic step forward," said Susanna Greer, director of clinical research and immunology at the American Cancer Society. "It's been difficult to make a lot of progress in lymphoma, especially in non-Hodgkin lymphoma, ... Read more

Related support groups: Non-Hodgkin's Lymphoma, Follicular Lymphoma, Cutaneous T-cell Lymphoma, Burkitt Lymphoma, Diagnosis and Investigation, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Mycosis Fungoides, Peripheral T-cell Lymphoma

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia, Burkitt Lymphoma

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma

Related Drug Support Groups

methotrexate, Rituxan, rituximab, Revlimid, Imbruvica, Cytoxan, cyclophosphamide, Velcade, ibrutinib, view more... vincristine, doxorubicin, cytarabine, bortezomib, lenalidomide, mitoxantrone, Cytoxan Lyophilized, Neosar